{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:08:45Z","timestamp":1792807725168,"version":"4.5.0"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41569-020-00459-3","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T12:05:28Z","timestamp":1603800328000},"page":"276-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Stroke prevention strategies in high-risk patients with atrial fibrillation"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6762-3187","authenticated-orcid":false,"given":"Agnieszka","family":"Kotalczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Kalarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6285-6902","authenticated-orcid":false,"given":"Tatjana S.","family":"Potpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"459_CR1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip, G. Y. H. The ABC pathway: an integrated approach to improve AF management. Nat. Rev. Cardiol. 14, 627\u2013628 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"459_CR2","doi-asserted-by":"publisher","unstructured":"Hindricks G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612 (2020).","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"459_CR3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip, G. Y. H. et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 154, 1121\u20131201 (2018).","journal-title":"Chest"},{"key":"459_CR4","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","volume":"117","author":"GYH Lip","year":"2017","unstructured":"Lip, G. Y. H., Freedman, B., de Caterina, R. & Potpara, T. S. Stroke prevention in atrial fibrillation: past, present and future comparing the guidelines and practical decision-making. Thromb. Haemost. 117, 1230\u20131239 (2017).","journal-title":"Thromb. Haemost."},{"key":"459_CR5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.mayocp.2017.05.023","volume":"92","author":"M Mazurek","year":"2017","unstructured":"Mazurek, M. et al. Guideline-adherent antithrombotic treatment improves outcomes in patients with atrial fibrillation: insights from the community-based Darlington Atrial Fibrillation Registry. Mayo Clin. Proc. 92, 1203\u20131213 (2017).","journal-title":"Mayo Clin. Proc."},{"key":"459_CR6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","volume":"1","author":"Y Wan","year":"2008","unstructured":"Wan, Y. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ. Cardiovasc. Qual. Outcomes 1, 84\u201391 (2008).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"459_CR7","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1160\/TH13-09-0734","volume":"111","author":"GYH Lip","year":"2014","unstructured":"Lip, G. Y. H. et al. Patient outcomes using the European label for dabigatran: a post-hoc analysis from the RE-LY database. Thromb. Haemost. 111, 933\u2013942 (2014).","journal-title":"Thromb. Haemost."},{"key":"459_CR8","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/STROKEAHA.118.024210","volume":"50","author":"S-R Lee","year":"2019","unstructured":"Lee, S.-R. et al. Optimal rivaroxaban dose in Asian patients with atrial fibrillation and normal or mildly impaired renal function. Stroke 50, 1140\u20131148 (2019).","journal-title":"Stroke"},{"key":"459_CR9","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1161\/STROKEAHA.119.025623","volume":"50","author":"WH Cheng","year":"2019","unstructured":"Cheng, W. H. et al. Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation. Stroke 50, 2574\u20132577 (2019).","journal-title":"Stroke"},{"key":"459_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","volume":"4","author":"MH Eckman","year":"2011","unstructured":"Eckman, M. H., Singer, D. E., Rosand, J. & Greenberg, S. M. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 4, 14\u201321 (2011).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"459_CR11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.amjmed.2016.03.024","volume":"129","author":"M Proietti","year":"2016","unstructured":"Proietti, M. & Lip, G. Y. H. Major outcomes in atrial fibrillation patients with one risk factor: impact of time in therapeutic range observations from the SPORTIF trials. Am. J. Med. 129, 1110\u20131116 (2016).","journal-title":"Am. J. Med."},{"key":"459_CR12","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","volume":"118","author":"ED Borre","year":"2018","unstructured":"Borre, E. D. et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb. Haemost. 118, 2171\u20132187 (2018).","journal-title":"Thromb. Haemost."},{"key":"459_CR13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","volume":"118","author":"TF Chao","year":"2018","unstructured":"Chao, T. F. et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb. Haemost. 118, 768\u2013777 (2018).","journal-title":"Thromb. Haemost."},{"key":"459_CR14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","volume":"71","author":"TF Chao","year":"2018","unstructured":"Chao, T. F. et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J. Am. Coll. Cardiol. 71, 122\u2013132 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR15","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1055\/s-0038-1651482","volume":"118","author":"M Yoon","year":"2018","unstructured":"Yoon, M. et al. Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in Asian patients with atrial fibrillation: a nationwide cohort study. Thromb. Haemost. 118, 1296\u20131304 (2018).","journal-title":"Thromb. Haemost."},{"key":"459_CR16","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1055\/s-0039-1696955","volume":"119","author":"MA Esteve-Pastor","year":"2019","unstructured":"Esteve-Pastor, M. A. et al. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb. Haemost. 119, 1901\u20131919 (2019).","journal-title":"Thromb. Haemost."},{"key":"459_CR17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/STROKEAHA.118.024305","volume":"50","author":"JM Rivera-Caravaca","year":"2019","unstructured":"Rivera-Caravaca, J. M. et al. Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores. Stroke 50, 1372\u20131379 (2019).","journal-title":"Stroke"},{"key":"459_CR18","first-page":"465","volume":"111","author":"S LaHaye","year":"2013","unstructured":"LaHaye, S. et al. Evaluation of patients\u2019 attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb. Haemost. 111, 465\u2013473 (2013).","journal-title":"Thromb. Haemost."},{"key":"459_CR19","doi-asserted-by":"publisher","unstructured":"Potpara T. S. et al. The 4S-AF scheme (stroke risk; symptoms; severity of burden; substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. Thromb. Haemost. https:\/\/doi.org\/10.1055\/s-0040-1716408 (2020).","DOI":"10.1055\/s-0040-1716408"},{"key":"459_CR20","doi-asserted-by":"publisher","unstructured":"Arbelo E. et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace https:\/\/doi.org\/10.1093\/europace\/euaa253 (2020).","DOI":"10.1093\/europace\/euaa253"},{"key":"459_CR21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/europace\/euz258","volume":"22","author":"M Glikson","year":"2020","unstructured":"Glikson, M. et al. EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion\u2013an update. Europace 22, 184 (2020).","journal-title":"Europace"},{"key":"459_CR22","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.09.1085","volume":"70","author":"GF Tomaselli","year":"2017","unstructured":"Tomaselli, G. F. et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J. Am. Coll. Cardiol. 70, 3042\u20133067 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR23","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/ndt\/gfs416","volume":"27","author":"D Zimmerman","year":"2012","unstructured":"Zimmerman, D. et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol. Dial. Transpl. 27, 3816\u20133822 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"459_CR24","doi-asserted-by":"publisher","unstructured":"Ding W. Y., Gupta D., Wong C. F. & Lip G. Y. H. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc. Res. https:\/\/doi.org\/10.1093\/cvr\/cvaa258 (2020).","DOI":"10.1093\/cvr\/cvaa258"},{"key":"459_CR25","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","volume":"57","author":"R Marinigh","year":"2011","unstructured":"Marinigh, R., Lane, D. A. & Lip, G. Y. H. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J. Am. Coll. Cardiol. 57, 1339\u20131348 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep30271","volume":"6","author":"G Boriani","year":"2016","unstructured":"Boriani, G. et al. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci. Rep. 6, 1\u201311. (2016).","journal-title":"Sci. Rep."},{"key":"459_CR27","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2016.06.057","volume":"68","author":"YC Lau","year":"2016","unstructured":"Lau, Y. C., Proietti, M., Guiducci, E., Blann, A. D. & Lip, G. Y. H. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J. Am. Coll. Cardiol. 68, 1452\u20131464 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2017.12.017","volume":"198","author":"L Fauchier","year":"2018","unstructured":"Fauchier, L. et al. Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. Am. Heart J. 198, 39\u201345 (2018).","journal-title":"Am. Heart J."},{"key":"459_CR29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.amjcard.2012.12.045","volume":"111","author":"V Rold\u00e1n","year":"2013","unstructured":"Rold\u00e1n, V. et al. Renal impairment in a \u201creal-life\u201d cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am. J. Cardiol. 111, 1159\u20131164 (2013).","journal-title":"Am. J. Cardiol."},{"key":"459_CR30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/joa3.12306","volume":"36","author":"Y Bai","year":"2020","unstructured":"Bai, Y., Shantsila, A. & Lip, G. Y. H. Clinical outcomes associated with kidney function changes in anticoagulated atrial fibrillation patients: an ancillary analysis from the BOREALIS trial. J. Arrhythmia 36, 282\u2013288 (2020).","journal-title":"J. Arrhythmia"},{"key":"459_CR31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2215\/CJN.10921015","volume":"11","author":"N Bansal","year":"2016","unstructured":"Bansal, N. et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin. J. Am. Soc. Nephrol. 11, 1189\u20131196 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"459_CR32","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","volume":"65","author":"M B\u00f6hm","year":"2015","unstructured":"B\u00f6hm, M. et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J. Am. Coll. Cardiol. 65, 2481\u20132493 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","volume":"75","author":"T Kuno","year":"2020","unstructured":"Kuno, T. et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J. Am. Coll. Cardiol. 75, 273\u2013285 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/nep.13207","volume":"24","author":"J Tan","year":"2019","unstructured":"Tan, J. et al. Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation. Nephrology 24, 234\u2013244 (2019).","journal-title":"Nephrology"},{"key":"459_CR35","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.2009030319","volume":"20","author":"KE Chan","year":"2009","unstructured":"Chan, K. E., Michael Lazarus, J., Thadhani, R. & Hakim, R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am. Soc. Nephrol. 20, 2223\u20132233 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"459_CR36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","volume":"33","author":"L Friberg","year":"2012","unstructured":"Friberg, L., Rosenqvist, M. & Lip, G. Y. H. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur. Heart J. 33, 1500\u20131510 (2012).","journal-title":"Eur. Heart J."},{"key":"459_CR37","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","volume":"64","author":"AN Bonde","year":"2014","unstructured":"Bonde, A. N. et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J. Am. Coll. Cardiol. 64, 2471\u20132482 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ejh.13383","volume":"104","author":"B Miao","year":"2020","unstructured":"Miao, B., Sood, N., Bunz, T. J. & Coleman, C. I. Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. Eur. J. Haematol. 104, 328\u2013335 (2020).","journal-title":"Eur. J. Haematol."},{"key":"459_CR39","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","volume":"138","author":"KC Siontis","year":"2018","unstructured":"Siontis, K. C. et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 138, 1519\u20131529 (2018).","journal-title":"Circulation"},{"key":"459_CR40","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January, C. T. et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 140, e125\u2013e151 (2019).","journal-title":"Circulation"},{"key":"459_CR41","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cjca.2016.07.591","volume":"32","author":"L Macle","year":"2016","unstructured":"Macle, L. et al. 2016 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can. J. Cardiol. 32, 1170\u20131185 (2016).","journal-title":"Can. J. Cardiol."},{"key":"459_CR42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","volume":"33","author":"CE Chiang","year":"2017","unstructured":"Chiang, C. E. et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J. Arrhythmia 33, 345\u2013367 (2017).","journal-title":"J. Arrhythmia"},{"key":"459_CR43","unstructured":"Pokorney, S. D. RENalhemodialysis patients ALlocatedapixaban versus warfarin in Atrial Fibrillation (RENAL-AF). https:\/\/www.acc.org\/~\/media\/Clinical\/PDF-Files\/Approved-PDFs\/2019\/11\/11\/AHA19\/Nov16-Sat\/345pm-Apixaban-vs-Warfarin-aha-2019.pdf (2019)."},{"key":"459_CR44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022690","volume":"8","author":"H Reinecke","year":"2018","unstructured":"Reinecke, H. et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open 8, e022690 (2018).","journal-title":"BMJ Open"},{"key":"459_CR45","doi-asserted-by":"publisher","unstructured":"Okumura K. et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2012883 (2020).","DOI":"10.1056\/NEJMoa2012883"},{"key":"459_CR46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","volume":"6","author":"M Zoni-Berisso","year":"2014","unstructured":"Zoni-Berisso, M., Lercari, F., Carazza, T. & Domenicucci, S. Epidemiology of atrial fbrillation: European perspective. Clin. Epidemiol. 6, 213\u2013220 (2014).","journal-title":"Clin. Epidemiol."},{"key":"459_CR47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip, G. Y. H. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 137, 263\u2013272 (2010).","journal-title":"Chest"},{"key":"459_CR48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/STROKEAHA.114.007199","volume":"46","author":"GYH Lip","year":"2015","unstructured":"Lip, G. Y. H., Clementy, N., Pericart, L., Banerjee, A. & Fauchier, L. Stroke and major bleeding risk in elderly patients aged \u226575 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke 46, 143\u2013150 (2015).","journal-title":"Stroke"},{"key":"459_CR49","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.hrthm.2016.03.049","volume":"13","author":"EW Chan","year":"2016","unstructured":"Chan, E. W. et al. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: a population-wide cohort study. Heart Rhythm 13, 1581\u20131588 (2016).","journal-title":"Heart Rhythm"},{"key":"459_CR50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.117.031658","volume":"138","author":"TF Chao","year":"2018","unstructured":"Chao, T. F. et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 138, 37\u201347 (2018).","journal-title":"Circulation"},{"key":"459_CR51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J Mant","year":"2007","unstructured":"Mant, J. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370, 493\u2013503 (2007).","journal-title":"Lancet"},{"key":"459_CR52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/europace\/euaa153","volume":"22","author":"L Fauchier","year":"2020","unstructured":"Fauchier, L. et al. Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study. Europace 22, 205\u2013215 (2020).","journal-title":"Europace"},{"key":"459_CR53","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3233\/JAD-170575","volume":"61","author":"A Subic","year":"2018","unstructured":"Subic, A. et al. Treatment of atrial fibrillation in patients with dementia: a cohort study from the Swedish Dementia Registry. J. Alzheimers Dis. 61, 1119\u20131128 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"459_CR54","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.chest.2019.11.025","volume":"157","author":"TF Chao","year":"2020","unstructured":"Chao, T. F. et al. Comparing the effectiveness and safety of nonvitamin K antagonist oral anticoagulants and warfarin in elderly Asian patients with atrial fibrillation: a nationwide cohort study. Chest 157, 1266\u20131277 (2020).","journal-title":"Chest"},{"key":"459_CR55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ageing\/afl129","volume":"36","author":"A Rash","year":"2007","unstructured":"Rash, A. et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 36, 151\u2013156 (2007).","journal-title":"Age Ageing"},{"key":"459_CR56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.archger.2018.12.013","volume":"81","author":"D Caldeira","year":"2019","unstructured":"Caldeira, D. et al. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. Arch. Gerontol. Geriatr. 81, 209\u2013214 (2019).","journal-title":"Arch. Gerontol. Geriatr."},{"key":"459_CR57","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jgs.12799","volume":"62","author":"P Sardar","year":"2014","unstructured":"Sardar, P., Chatterjee, S., Chaudhari, S. & Lip, G. Y. H. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J. Am. Geriatr. Soc. 62, 857\u2013864 (2014).","journal-title":"J. Am. Geriatr. Soc."},{"key":"459_CR58","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/jgs.15956","volume":"67","author":"S Deitelzweig","year":"2019","unstructured":"Deitelzweig, S. et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. J. Am. Geriatr. Soc. 67, 1662\u20131671 (2019).","journal-title":"J. Am. Geriatr. Soc."},{"key":"459_CR59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jgs.13200","volume":"63","author":"O Bahri","year":"2015","unstructured":"Bahri, O. et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J. Am. Geriatr. Soc. 63, 71\u201376 (2015).","journal-title":"J. Am. Geriatr. Soc."},{"key":"459_CR60","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ageing\/afv071","volume":"44","author":"A Wolff","year":"2015","unstructured":"Wolff, A., Shantsila, E., Lip, G. Y. H. & Lane, D. A. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age Ageing 44, 874\u2013878 (2015).","journal-title":"Age Ageing"},{"key":"459_CR61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.15-1095","volume":"149","author":"Y Yamashita","year":"2016","unstructured":"Yamashita, Y. et al. Clinical characteristics and outcomes in extreme elderly (age \u226585 years) Japanese patients with atrial fibrillation: the Fushimi AF Registry. Chest 149, 401\u2013412 (2016).","journal-title":"Chest"},{"key":"459_CR62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jgs.16178","volume":"68","author":"JS Saczynski","year":"2020","unstructured":"Saczynski, J. S. et al. Geriatric elements and oral anticoagulant prescribing in older atrial fibrillation patients: SAGE-AF. J. Am. Geriatr. Soc. 68, 147\u2013154 (2020).","journal-title":"J. Am. Geriatr. Soc."},{"key":"459_CR63","first-page":"47","volume":"22","author":"M Mazurek","year":"2020","unstructured":"Mazurek, M. et al. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace 22, 47\u201357 (2020).","journal-title":"Europace"},{"key":"459_CR64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2019.01.005","volume":"211","author":"M Madhavan","year":"2019","unstructured":"Madhavan, M. et al. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am. Heart J. 211, 77\u201389 (2019).","journal-title":"Am. Heart J."},{"key":"459_CR65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1055\/s-0039-1683429","volume":"119","author":"TS Field","year":"2019","unstructured":"Field, T. S. et al. Incident atrial fibrillation, dementia and the role of anticoagulation: a population-based cohort study. Thromb. Haemost. 119, 981\u2013991 (2019).","journal-title":"Thromb. Haemost."},{"key":"459_CR66","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz386","volume":"40","author":"D Kim","year":"2019","unstructured":"Kim, D. et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. Eur. Heart J. 40, 2313\u20132323 (2019).","journal-title":"Eur. Heart J."},{"key":"459_CR67","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011358","volume":"8","author":"M S\u00f8gaard","year":"2019","unstructured":"S\u00f8gaard, M. et al. Nonvitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients and risk of dementia: a nationwide propensity-weighted cohort study. J. Am. Heart Assoc. 8, e011358 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"459_CR68","volume":"9","author":"G Banerjee","year":"2020","unstructured":"Banerjee, G. et al. Cognitive impairment before atrial fibrillation\u2013related ischemic events: neuroimaging and prognostic associations. J. Am. Heart Assoc. 9, e014537 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"459_CR69","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1161\/HYPERTENSIONAHA.119.14388","volume":"75","author":"D Kim","year":"2020","unstructured":"Kim, D. et al. Blood pressure control and dementia risk in midlife patients with atrial fibrillation. Hypertension 75, 1296\u20131304 (2020).","journal-title":"Hypertension"},{"key":"459_CR70","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jacc.2018.10.077","volume":"73","author":"HC Diener","year":"2019","unstructured":"Diener, H. C., Hart, R. G., Koudstaal, P. J., Lane, D. A. & Lip, G. Y. H. Atrial fibrillation and cognitive function: JACC review topic of the week. J. Am. Coll. Cardiol. 73, 612\u2013619 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/qjmed\/hct129","volume":"106","author":"S Udompanich","year":"2013","unstructured":"Udompanich, S., Lip, G. Y. H., Apostolakis, S. & Lane, D. A. Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. QJM 106, 795\u2013802 (2013).","journal-title":"QJM"},{"key":"459_CR72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2018.05.016","volume":"55","author":"M Proietti","year":"2018","unstructured":"Proietti, M. et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: a comparison between EORP-AF pilot and EHS-AF registries. Eur. J. Intern. Med. 55, 28\u201334 (2018).","journal-title":"Eur. J. Intern. Med."},{"key":"459_CR73","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014932","volume":"9","author":"M Proietti","year":"2020","unstructured":"Proietti, M., Romiti, G. F., Olshansky, B., Lane, D. A. & Lip, G. Y. H. Comprehensive management with the ABC (Atrial Fibrillation Better Care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J. Am. Heart Assoc. 9, e014932 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"459_CR74","doi-asserted-by":"crossref","first-page":"f329","DOI":"10.1093\/europace\/eux322","volume":"20","author":"BD Jani","year":"2018","unstructured":"Jani, B. D. et al. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. Europace 20, f329\u2013f336 (2018).","journal-title":"Europace"},{"key":"459_CR75","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.mayocp.2019.06.012","volume":"94","author":"M Proietti","year":"2019","unstructured":"Proietti, M. et al. Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. Mayo Clin. Proc. 94, 2427\u20132436 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"459_CR76","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","volume":"105","author":"M Proietti","year":"2016","unstructured":"Proietti, M., Raparelli, V., Olshansky, B. & Lip, G. Y. H. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin. Res. Cardiol. 105, 412\u2013420 (2016).","journal-title":"Clin. Res. Cardiol."},{"key":"459_CR77","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","volume":"133","author":"JP Piccini","year":"2016","unstructured":"Piccini, J. P. et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 133, 352\u2013360 (2016).","journal-title":"Circulation"},{"key":"459_CR78","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2020-001257","volume":"7","author":"C Gallagher","year":"2020","unstructured":"Gallagher, C. et al. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart 7, e001257 (2020).","journal-title":"Open Heart"},{"key":"459_CR79","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano, R. P. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369, 2093\u20132104 (2013).","journal-title":"N. Engl. J. Med."},{"key":"459_CR80","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883\u2013891 (2011).","journal-title":"N. Engl. J. Med."},{"key":"459_CR81","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981\u2013992 (2011).","journal-title":"N. Engl. J. Med."},{"key":"459_CR82","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139\u20131151 (2009).","journal-title":"N. Engl. J. Med."},{"key":"459_CR83","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/STROKEAHA.116.012945","volume":"47","author":"TP Ottosen","year":"2016","unstructured":"Ottosen, T. P. et al. Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage. Stroke 47, 1837\u20131843 (2016).","journal-title":"Stroke"},{"key":"459_CR84","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","volume":"132","author":"PB Nielsen","year":"2015","unstructured":"Nielsen, P. B. et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 132, 517\u2013525 (2015).","journal-title":"Circulation"},{"key":"459_CR85","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.115.019794","volume":"133","author":"T-F Chao","year":"2016","unstructured":"Chao, T.-F. et al. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 133, 1540\u20131547 (2016).","journal-title":"Circulation"},{"key":"459_CR86","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","volume":"48","author":"SB Murthy","year":"2017","unstructured":"Murthy, S. B. et al. Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke 48, 1594\u20131600 (2017).","journal-title":"Stroke"},{"key":"459_CR87","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5853\/jos.2018.02243","volume":"21","author":"S Perreault","year":"2019","unstructured":"Perreault, S. et al. Anticoagulants in older patients with nonvalvular atrial fibrillation after intracranial hemorrhage. J. Stroke 21, 195\u2013206 (2019).","journal-title":"J. Stroke"},{"key":"459_CR88","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/jamainternmed.2016.9369","volume":"177","author":"PB Nielsen","year":"2017","unstructured":"Nielsen, P. B., Larsen, T. B., Skj\u00f8th, F. & Lip, G. Y. H. Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Intern. Med. 177, 563\u2013570 (2017).","journal-title":"JAMA Intern. Med."},{"key":"459_CR89","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/STROKEAHA.119.028030","volume":"51","author":"SR Lee","year":"2020","unstructured":"Lee, S. R. et al. Oral anticoagulation in Asian patients with atrial fibrillation and a history of intracranial hemorrhage. Stroke 51, 416\u2013423 (2020).","journal-title":"Stroke"},{"key":"459_CR90","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03996772 (2020)."},{"key":"459_CR91","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03153150 (2020)."},{"key":"459_CR92","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/17474086.2019.1647779","volume":"12","author":"M Kozie\u0142","year":"2019","unstructured":"Kozie\u0142, M., Ding, W. Y., Kalarus, Z. & Lip, G. Y. H. Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding. Expert Rev. Hematol. 12, 845\u2013855 (2019).","journal-title":"Expert Rev. Hematol."},{"key":"459_CR93","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11883-018-0733-y","volume":"20","author":"Y-G Li","year":"2018","unstructured":"Li, Y.-G. & Lip, G. Y. H. Anticoagulation resumption after intracerebral hemorrhage. Curr. Atheroscler. Rep. 20, 32 (2018).","journal-title":"Curr. Atheroscler. Rep."},{"key":"459_CR94","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(18)30145-5","volume":"17","author":"D Wilson","year":"2018","unstructured":"Wilson, D. et al. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol. 17, 539\u2013547 (2018).","journal-title":"Lancet Neurol."},{"key":"459_CR95","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","volume":"46","author":"JC Hemphill","year":"2015","unstructured":"Hemphill, J. C. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 46, 2032\u20132060 (2015).","journal-title":"Stroke"},{"key":"459_CR96","first-page":"1455","volume":"38","author":"S Halvorsen","year":"2017","unstructured":"Halvorsen, S. et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology working group on thrombosis. Eur. Heart J. 38, 1455\u20131462 (2017).","journal-title":"Eur. Heart J."},{"key":"459_CR97","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1160\/TH16-12-0961","volume":"117","author":"JM Rivera-Caravaca","year":"2017","unstructured":"Rivera-Caravaca, J. M. et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb. Haemost. 117, 1448\u20131454 (2017).","journal-title":"Thromb. Haemost."},{"key":"459_CR98","doi-asserted-by":"publisher","unstructured":"Rasmussen P. V. et al. Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation. Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz964 (2020).","DOI":"10.1093\/eurheartj\/ehz964"},{"key":"459_CR99","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1160\/TH15-01-0063","volume":"114","author":"C Chai-Adisaksopha","year":"2015","unstructured":"Chai-Adisaksopha, C., Hillis, C., Monreal, M., Witt, D. M. & Crowther, M. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding: a meta-analysis. Thromb. Haemost. 114, 819\u2013825 (2015).","journal-title":"Thromb. Haemost."},{"key":"459_CR100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2019.01.020","volume":"175","author":"D Little","year":"2019","unstructured":"Little, D. et al. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis. Thromb. Res. 175, 102\u2013109 (2019).","journal-title":"Thromb. Res."},{"key":"459_CR101","doi-asserted-by":"crossref","first-page":"h5876","DOI":"10.1136\/bmj.h5876","volume":"351","author":"L Staerk","year":"2015","unstructured":"Staerk, L. et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort STUDY. BMJ 351, h5876 (2015).","journal-title":"BMJ"},{"key":"459_CR102","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","volume":"113","author":"W Qureshi","year":"2014","unstructured":"Qureshi, W. et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am. J. Cardiol. 113, 662\u2013668 (2014).","journal-title":"Am. J. Cardiol."},{"key":"459_CR103","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff, C. T. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383, 955\u2013962 (2014).","journal-title":"Lancet"},{"key":"459_CR104","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2018.03.053","volume":"261","author":"M Proietti","year":"2018","unstructured":"Proietti, M. et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis. Int. J. Cardiol. 261, 84\u201391 (2018).","journal-title":"Int. J. Cardiol."},{"key":"459_CR105","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(00)02085-7","volume":"355","author":"E Berge","year":"2000","unstructured":"Berge, E., Abdelnoor, M., Nakstad, P. H. & Sandset, P. M. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet 355, 1205\u20131210 (2000).","journal-title":"Lancet"},{"key":"459_CR106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/phar.2345","volume":"40","author":"MA Smythe","year":"2020","unstructured":"Smythe, M. A., Parker, D., Garwood, C. L., Cuker, A. & Mess\u00e9, S. R. Timing of initiation of oral anticoagulation after acute ischemic stroke in patients with atrial fibrillation. Pharmacotherapy 40, 55\u201371 (2020).","journal-title":"Pharmacotherapy"},{"key":"459_CR107","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03759938 (2019)."},{"key":"459_CR108","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-2313-9","volume":"18","author":"S \u00c5sberg","year":"2017","unstructured":"\u00c5sberg, S. et al. Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial. Trials 18, 581 (2017).","journal-title":"Trials"},{"key":"459_CR109","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","volume":"46","author":"M Paciaroni","year":"2015","unstructured":"Paciaroni, M. et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke 46, 2175\u20132182 (2015).","journal-title":"Stroke"},{"key":"459_CR110","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ana.25489","volume":"85","author":"DJ Seiffge","year":"2019","unstructured":"Seiffge, D. J. et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann. Neurol. 85, 823\u2013834 (2019).","journal-title":"Ann. Neurol."},{"key":"459_CR111","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1747493016632239","volume":"11","author":"S Arihiro","year":"2016","unstructured":"Arihiro, S. et al. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int. J. Stroke 11, 565\u2013574 (2016).","journal-title":"Int. J. Stroke"},{"key":"459_CR112","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/1747493017700663","volume":"12","author":"G Ntaios","year":"2017","unstructured":"Ntaios, G., Papavasileiou, V., Diener, H.-C., Makaritsis, K. & Michel, P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int. J. Stroke 12, 589\u2013596 (2017).","journal-title":"Int. J. Stroke"},{"key":"459_CR113","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan, W. N. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 45, 2160\u20132236 (2014).","journal-title":"Stroke"},{"key":"459_CR114","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/1747493017743062","volume":"13","author":"T Wein","year":"2018","unstructured":"Wein, T. et al. Canadian stroke best practice recommendations: secondary prevention of stroke, sixth edition practice guidelines, update 2017. Int. J. Stroke 13, 420\u2013443 (2018).","journal-title":"Int. J. Stroke"},{"key":"459_CR115","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel, J. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 39, 1330\u20131393 (2018).","journal-title":"Eur. Heart J."},{"key":"459_CR116","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-123-11-199512010-00001","volume":"123","author":"WJ Manning","year":"1995","unstructured":"Manning, W. J. et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann. Intern. Med. 123, 817\u2013822 (1995).","journal-title":"Ann. Intern. Med."},{"key":"459_CR117","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","volume":"61","author":"JL Blackshear","year":"1996","unstructured":"Blackshear, J. L. & Odell, J. A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann. Thorac. Surg. 61, 755\u2013759 (1996).","journal-title":"Ann. Thorac. Surg."},{"key":"459_CR118","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-018-0350-9","volume":"23","author":"S Reers","year":"2018","unstructured":"Reers, S. et al. Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis. Eur. J. Med. Res. 23, 49 (2018).","journal-title":"Eur. J. Med. Res."},{"key":"459_CR119","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.amjcard.2014.12.016","volume":"115","author":"MM Zylla","year":"2015","unstructured":"Zylla, M. M. et al. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. Am. J. Cardiol. 115, 635\u2013640 (2015).","journal-title":"Am. J. Cardiol."},{"key":"459_CR120","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-016-0235-8","volume":"21","author":"S Reers","year":"2016","unstructured":"Reers, S. et al. Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists. Eur. J. Med. Res. 21, 41 (2016).","journal-title":"Eur. J. Med. Res."},{"key":"459_CR121","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/europace\/euu347","volume":"17","author":"M Petersen","year":"2015","unstructured":"Petersen, M. et al. Left atrial appendage morphology is closely associated with specific echocardiographic flow pattern in patients with atrial fibrillation. Europace 17, 539\u2013545 (2015).","journal-title":"Europace"},{"key":"459_CR122","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4103\/0366-6999.191744","volume":"129","author":"YY Chen","year":"2016","unstructured":"Chen, Y. Y. et al. Effect of metabolic syndrome on risk stratification for left atrial or left atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. Chin. Med. J. 129, 2395\u20132402 (2016).","journal-title":"Chin. Med. J."},{"key":"459_CR123","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jcmg.2015.11.029","volume":"9","author":"D Kitkungvan","year":"2016","unstructured":"Kitkungvan, D. et al. Detection of LA and LAA thrombus by CMR in patients referred for pulmonary vein isolation. JACC Cardiovasc. Imaging 9, 809\u2013818 (2016).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"459_CR124","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1540-8167.2010.01729.x","volume":"21","author":"TW Wallace","year":"2010","unstructured":"Wallace, T. W. et al. Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. J. Cardiovasc. Electrophysiol. 21, 849\u2013852 (2010).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"459_CR125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2020.04.070","volume":"317","author":"M Shah","year":"2020","unstructured":"Shah, M. et al. Predictors of left atrial appendage thrombus despite NOAC use in nonvalvular atrial fibrillation and flutter. Int. J. Cardiol. 317, 86\u201390 (2020).","journal-title":"Int. J. Cardiol."},{"key":"459_CR126","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2017.07.048","volume":"249","author":"E Bertaglia","year":"2017","unstructured":"Bertaglia, E. et al. NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world. Int. J. Cardiol. 249, 179\u2013183 (2017).","journal-title":"Int. J. Cardiol."},{"key":"459_CR127","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/europace\/euz257","volume":"22","author":"MM Farkowski","year":"2020","unstructured":"Farkowski, M. M. et al. Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. Europace 22, 162\u2013169 (2020).","journal-title":"Europace"},{"key":"459_CR128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.joa.2016.01.009","volume":"32","author":"Y Miwa","year":"2016","unstructured":"Miwa, Y. et al. Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban. J. Arrhythmia 32, 233\u2013235 (2016).","journal-title":"J. Arrhythmia"},{"key":"459_CR129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ahj.2016.05.007","volume":"178","author":"GYH Lip","year":"2016","unstructured":"Lip, G. Y. H. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am. Heart J. 178, 126\u2013134 (2016).","journal-title":"Am. Heart J."},{"key":"459_CR130","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jacc.2020.01.057","volume":"75","author":"B Lattuca","year":"2020","unstructured":"Lattuca, B. et al. Antithrombotic therapy for patients with left ventricular mural thrombus. J. Am. Coll. Cardiol. 75, 1676\u20131685 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR131","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11239-018-1656-8","volume":"46","author":"AST Leow","year":"2018","unstructured":"Leow, A. S. T., Sia, C. H., Tan, B. Y. Q. & Loh, J. P. Y. A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus. J. Thromb. Thrombolysis 46, 68\u201373 (2018).","journal-title":"J. Thromb. Thrombolysis"},{"key":"459_CR132","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","volume":"5","author":"AA Robinson","year":"2020","unstructured":"Robinson, A. A. et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 5, 685\u2013692 (2020).","journal-title":"JAMA Cardiol."},{"key":"459_CR133","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","volume":"65","author":"DR Holmes","year":"2015","unstructured":"Holmes, D. R. et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J. Am. Coll. Cardiol. 65, 2614\u20132623 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR134","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","volume":"312","author":"VY Reddy","year":"2014","unstructured":"Reddy, V. Y. et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation a randomized clinical trial. JAMA 312, 1988\u20131998 (2014).","journal-title":"JAMA"},{"key":"459_CR135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/heartjnl-2016-309782","volume":"103","author":"S Sahay","year":"2017","unstructured":"Sahay, S. et al. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. Heart 103, 139\u2013147 (2017).","journal-title":"Heart"},{"key":"459_CR136","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10840-019-00635-7","volume":"58","author":"J Brachmann","year":"2019","unstructured":"Brachmann, J. et al. Interventional occlusion of left atrial appendage in patients with atrial fibrillation. Acute and long-term outcome of occluder implantation in the LAARGE registry. J. Interv. Card. Electrophysiol. 58, 273\u2013280 (2019).","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"459_CR137","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","volume":"14","author":"LV Boersma","year":"2017","unstructured":"Boersma, L. V. et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 14, 1302\u20131308 (2017).","journal-title":"Heart Rhythm"},{"key":"459_CR138","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.hrthm.2017.10.007","volume":"15","author":"J Mandrola","year":"2018","unstructured":"Mandrola, J., Foy, A. & Naccarelli, G. Percutaneous left atrial appendage closure is not ready for routine clinical use. Heart Rhythm 15, 298\u2013301 (2018).","journal-title":"Heart Rhythm"},{"key":"459_CR139","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.002212","volume":"1","author":"MJ Swaans","year":"2012","unstructured":"Swaans, M. J., Post, M. C., Rensing, B. J. W. M. & Boersma, L. V. A. Ablation for atrial fibrillation in combination with left atrial appendage closure: first results of a feasibility study. J. Am. Heart Assoc. 1, e002212 (2012).","journal-title":"J. Am. Heart Assoc."},{"key":"459_CR140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/europace\/euaa225","volume":"22","author":"KP Phillips","year":"2020","unstructured":"Phillips, K. P. et al. Combining left atrial appendage closure and catheter ablation for atrial fibrillation: 2-year outcomes from a multinational registry. Europace 22, 225\u2013231 (2020).","journal-title":"Europace"},{"key":"459_CR141","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/europace\/euy025","volume":"20","author":"L Wintgens","year":"2018","unstructured":"Wintgens, L. et al. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. Europace 20, 1783\u20131789 (2018).","journal-title":"Europace"},{"key":"459_CR142","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/eurheartj\/ehw007","volume":"37","author":"AN Ganesan","year":"2016","unstructured":"Ganesan, A. N. et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur. Heart J. 37, 1591\u20131602 (2016).","journal-title":"Eur. Heart J."},{"key":"459_CR143","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jce.12864","volume":"27","author":"R Passman","year":"2016","unstructured":"Passman, R. et al. Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assessment with an insertable cardiac monitor: the Rhythm Evaluation for Anticoagulation with Continuous Monitoring (REACT.COM) pilot study. J. Cardiovasc. Electrophysiol. 27, 264\u2013270 (2016).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"459_CR144","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.hrthm.2018.06.027","volume":"15","author":"JW Waks","year":"2018","unstructured":"Waks, J. W. et al. Intermittent anticoagulation guided by continuous atrial fibrillation burden monitoring using dual-chamber pacemakers and implantable cardioverter-defibrillators: results from the Tailored Anticoagulation for Non-Continuous Atrial Fibrillation (TACTIC-AF) pilot study. Heart Rhythm 15, 1601\u20131607 (2018).","journal-title":"Heart Rhythm"},{"key":"459_CR145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/jce.13859","volume":"30","author":"ES Zado","year":"2019","unstructured":"Zado, E. S. et al. \u201cAs needed\u201d nonvitamin K antagonist oral anticoagulants for infrequent atrial fibrillation episodes following atrial fibrillation ablation guided by diligent pulse monitoring: a feasibility study. J. Cardiovasc. Electrophysiol. 30, 631\u2013638 (2019).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"459_CR146","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10840-016-0192-8","volume":"48","author":"S Stavrakis","year":"2017","unstructured":"Stavrakis, S. et al. Intermittent vs. Continuous Anticoagulation theRapy in patiEnts with Atrial Fibrillation (iCARE-AF): a randomized pilot study. J. Interv. Card. Electrophysiol. 48, 51\u201360 (2017).","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"459_CR147","first-page":"e623","volume":"137","author":"LY Chen","year":"2018","unstructured":"Chen, L. Y. et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation 137, e623\u2013e644. (2018).","journal-title":"Circulation"},{"key":"459_CR148","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.119.041303","volume":"140","author":"RM Kaplan","year":"2019","unstructured":"Kaplan, R. M. et al. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score. Circulation 140, 1639\u20131646 (2019).","journal-title":"Circulation"},{"key":"459_CR149","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.hrthm.2011.04.022","volume":"8","author":"EG Daoud","year":"2011","unstructured":"Daoud, E. G. et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 8, 1416\u20131423 (2011).","journal-title":"Heart Rhythm"},{"key":"459_CR150","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","volume":"129","author":"M Brambatti","year":"2014","unstructured":"Brambatti, M. et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 129, 2094\u20132099 (2014).","journal-title":"Circulation"},{"key":"459_CR151","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","volume":"381","author":"MV Perez","year":"2019","unstructured":"Perez, M. V. et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N. Engl. J. Med. 381, 1909\u20131917 (2019).","journal-title":"N. Engl. J. Med."},{"key":"459_CR152","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.08.019","volume":"74","author":"Y Guo","year":"2019","unstructured":"Guo, Y. et al. Mobile photoplethysmographic technology to detect atrial fibrillation. J. Am. Coll. Cardiol. 74, 2365\u20132375 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"459_CR153","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2015.05.019","volume":"66","author":"JI Shen","year":"2015","unstructured":"Shen, J. I. et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am. J. Kidney Dis. 66, 677\u2013688 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"459_CR154","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.amjcard.2019.10.033","volume":"125","author":"A Makani","year":"2020","unstructured":"Makani, A. et al. Safety and efficacy of direct oral anticoagulants versus warfarin in patients with chronic kidney disease and atrial fibrillation. Am. J. Cardiol. 125, 210\u2013214 (2020).","journal-title":"Am. J. Cardiol."},{"key":"459_CR155","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.amjmed.2019.04.013","volume":"132","author":"CI Coleman","year":"2019","unstructured":"Coleman, C. I. et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am. J. Med. 132, 1078\u20131083 (2019).","journal-title":"Am. J. Med."},{"key":"459_CR156","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","volume":"131","author":"KE Chan","year":"2015","unstructured":"Chan, K. E., Edelman, E. R., Wenger, J. B., Thadhani, R. I. & Maddux, F. W. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131, 972\u2013979 (2015).","journal-title":"Circulation"},{"key":"459_CR157","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","volume":"152","author":"NS Abraham","year":"2017","unstructured":"Abraham, N. S., Noseworthy, P. A., Yao, X., Sangaralingham, L. R. & Shah, N. D. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology 152, 1014\u20131022.e1 (2017).","journal-title":"Gastroenterology"},{"key":"459_CR158","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/jnnp-2018-318890","volume":"90","author":"D Wilson","year":"2018","unstructured":"Wilson, D. et al. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. J. Neurol. Neurosurg. Psychiatry 90, 320\u2013325 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"459_CR159","doi-asserted-by":"publisher","unstructured":"Cobas Paz, R. et al. Impact of anticoagulation in patients with dementia and atrial fibrillation. Results of the CardioCHUVI-FA registry. Rev. Esp. Cardiol. (Engl. Ed.) https:\/\/doi.org\/10.1016\/j.rec.2019.10.025 (2020).","DOI":"10.1016\/j.rec.2019.10.025"},{"key":"459_CR160","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/jce.14176","volume":"30","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. Physical, cognitive, and psychosocial conditions in relation to anticoagulation satisfaction among elderly adults with atrial fibrillation: the SAGE-AF study. J. Cardiovasc. Electrophysiol. 30, 2508\u20132515 (2019).","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"459_CR161","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/heartjnl-2012-302843","volume":"99","author":"ACE Scowcroft","year":"2013","unstructured":"Scowcroft, A. C. E., Lee, S. & Mant, J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart 99, 127\u2013132 (2013).","journal-title":"Heart"},{"key":"459_CR162","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/01.STR.0000209239.71702.ce","volume":"37","author":"EM Hylek","year":"2006","unstructured":"Hylek, E. M. et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 37, 1075\u20131080 (2006).","journal-title":"Stroke"},{"key":"459_CR163","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/jth.13427","volume":"14","author":"G Bertozzo","year":"2016","unstructured":"Bertozzo, G. et al. Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. J. Thromb. Haemost. 14, 2124\u20132131 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"459_CR164","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/jgs.16335","volume":"68","author":"A Kapoor","year":"2020","unstructured":"Kapoor, A. et al. Geriatric conditions predict discontinuation of anticoagulation in long-term care residents with atrial fibrillation. J. Am. Geriatr. Soc. 68, 717\u2013724 (2020).","journal-title":"J. Am. Geriatr. Soc."},{"key":"459_CR165","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ana.25079","volume":"82","author":"A Biffi","year":"2017","unstructured":"Biffi, A. et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann. Neurol. 82, 755\u2013765 (2017).","journal-title":"Ann. Neurol."},{"key":"459_CR166","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jama.2015.10082","volume":"314","author":"A Biffi","year":"2015","unstructured":"Biffi, A. et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA 314, 904\u2013912 (2015).","journal-title":"JAMA"},{"key":"459_CR167","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1747493019828555","volume":"14","author":"JB Kuramatsu","year":"2019","unstructured":"Kuramatsu, J. B. & Huttner, H. B. Management of oral anticoagulation after intracerebral hemorrhage. Int. J. Stroke 14, 238\u2013246 (2019).","journal-title":"Int. J. Stroke"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-00459-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-00459-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-00459-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T13:44:46Z","timestamp":1723815886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-00459-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":167,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1038\/s41569-020-00459-3","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"21 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Y.H.L. has been a consultant for Bayer\/Janssen, BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Novartis and Verseon. G.Y.H.L. has been a speaker for Bayer, BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo and Medtronic. G.Y.H.L. received no fees for these activities personally. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}